Patents by Inventor Ruth Brack-Werner

Ruth Brack-Werner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10421749
    Abstract: The present invention relates to compounds and compositions for use in methods of treating and/or preventing conditions, disorders or diseases that are mediated or caused by a virus.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: September 24, 2019
    Assignees: HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), LEIBNIZINSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E. V. -HANS-KNÖLL-INSTITUT
    Inventors: Ruth Brack-Werner, Markus Helfer, Manfred Rösner, Martha Schneider, Ulrike Protzer, Christian Hertweck, Martina Werneburg
  • Publication number: 20180118725
    Abstract: The present invention relates to compounds and compositions for use in methods of treating and/or preventing conditions, disorders or diseases that are mediated or caused by a virus.
    Type: Application
    Filed: April 7, 2016
    Publication date: May 3, 2018
    Inventors: Ruth BRACK-WERNER, Markus HELFER, Manfred RÖSNER, Martha SCHNEIDER, Ulrike PROTZER, Christian HERTWECK, Martina WERNEBURG
  • Publication number: 20120020940
    Abstract: The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity.
    Type: Application
    Filed: September 24, 2009
    Publication date: January 26, 2012
    Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)
    Inventors: Jörg Durner, Christian Lindermayr, Ruth Brack-Werner
  • Publication number: 20110294721
    Abstract: The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid residues; or a p
    Type: Application
    Filed: September 24, 2009
    Publication date: December 1, 2011
    Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)
    Inventors: Jörg Durner, Christian Lindermayr, Ruth Brack-Werner
  • Publication number: 20080161199
    Abstract: The present invention refers to inventive fusion proteins, to a method for detecting protein-protein-interactions in living cells and cell lysates using these inventive fusion proteins. The present invention also refers to a screening method for identifying compounds suitable to modify, i.e. inhibit or enhance, protein-protein-interaction using these fusion proteins. Additionally a method for detecting cells is disclosed comprising an unknown protein that interacts with a known protein. Along with the inventive fusion proteins used for these methods encoding nucleic acids, corresponding vectors and host cells transfected accordingly are disclosed herewith.
    Type: Application
    Filed: December 22, 2005
    Publication date: July 3, 2008
    Applicant: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH
    Inventors: Horst Wolff, Andrea Brebeck, Manja Ziegler, Ruth Brack-Werner
  • Patent number: 7183047
    Abstract: The present invention relates to a reporter gene construct for the detection of the HIV Rev and HIV Tat proteins. Furthermore, the invention relates to a functionality test method for Rev and Rev fusion proteins prepared in a recombinant manner, a method of screening for sequences of different origin for their activity as an instability element, a method of screening for sequences which cause the transport out of the nucleus into the cytoplasm by binding to cellular or other viral shuttle proteins, as well as to a method for the detection of HIV-infected cells. The reporter gene construct according to the present invention, after it has been introduced into cells, in the presence of HIV Rev and HIV Tat proteins results in the formation of reporter proteins which may be used for quantitative/qualitative detection of the HIV Rev and HIV Tat proteins.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: February 27, 2007
    Assignee: GSF-Forschungszentrum für Umwelt und Gesundheit, GmbH
    Inventors: Ruth Brack-Werner, Markus Neumann, Horst Wolff, Volker Erfle
  • Publication number: 20030092032
    Abstract: The present invention relates to a reporter gene construct for the detection of the HIV Rev and HIV Tat proteins. Furthermore, the invention relates to a functionality test method for Rev and Rev fusion proteins prepared in a recombinant manner, a method of screening for sequences of different origin for their activity as an instability element, a method of screening for sequences which cause the transport out of the nucleus into the cytoplasm by binding to cellular or other viral shuttle proteins, as well as to a method for the detection of HIV-infected cells. The reporter gene construct according to the present invention, after it has been introduced into cells, in the presence of HIV Rev and HIV Tat proteins results in the formation of reporter proteins which may be used for quantitative/qualitative detection of the HIV Rev and HIV Tat proteins.
    Type: Application
    Filed: June 20, 2002
    Publication date: May 15, 2003
    Inventors: Ruth Brack-Werner, Markus Neumann, Horst Wolff, Volker Erfle